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Plasmacytoid dendritic cells (pDCs) exhibit both innate and adaptive functions. In particular they are the
main source of type I IFNs and directly impact T cell responses through antigen presentation. We have
previously demonstrated that during experimental autoimmune encephalomyelitis (EAE) initiation,
myelin-antigen presentation by pDCs is associated with suppressive Treg development and results in
attenuated EAE. Here, we show that pDCs transferred during acute disease phase confer recovery from
EAE. Clinical improvement is associated with migration of injected pDCs into inﬂamed CNS and is
dependent on the subsequent and selective chemerin-mediated recruitment of endogenous pDCs to the
CNS. The protective effect requires pDC pre-loading with myelin antigen, and is associated with the
modulation of CNS-inﬁltrating pDC phenotype and inhibition of CNS encephalitogenic T cells. This study
may pave the way for novel pDC-based cell therapies in autoimmune diseases, aiming at speciﬁcally
modulating pathogenic cells that induce and sustain autoimmune inﬂammation.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Plasmacytoid dendritic cells (pDCs) are the main producers of
type I interferons (IFN-I) in response to foreign nucleic acids,
thereby indirectly inﬂuencing immunity. They can also differentiate
into antigen presenting cells (APCs) to directly stimulate and
modulate T cell responses [1]. pDCs have been implicated in the
pathogenesis of many human inﬂammatory diseases and their
corresponding mouse models. For example, chronic pDC activation
and subsequent IFN-I production can promote autoimmune dis-
eases, such as lupus erythematosus (SLE) [2] and psoriasis [3].
Multiple Sclerosis (MS) is a chronic inﬂammatory disease of the
central nervous system (CNS). In MS patients, pDCs are present in
the cerebrospinal ﬂuid (CSF), leptomeninges and demyelinating
lesions [4,5]. The exact role of pDCs in the pathogenesis of MS isgues).
Ltd. This is an open access article ucontroversial, as they might have both pathogenic and protective
functions. In one hand, pDC-derived cytokines, including type-I IFN
and IL-6 induces pro-pathogenic Th1 and Th17 cells, which are
implicated in MS pathogenesis [6,7]. On the other hand, pDCs can
exert a protective role in MS through the production of type-I IFN
[8]. For instance, relapsing patients treated with IFN-b exhibit
reduced disease severity [9]. In experimental autoimmune
encephalomyelitis (EAE), the rodent model of MS, IFN-b and IFNAR-
deﬁciency exacerbates disease severity [10,11]. Furthermore, one
study suggests that pDCs inhibit pro-pathogenic conventional DCs
(cDCs) functions in the CNS and, consequently locally inhibit
encephalitogenic Th17 cells [12]. In addition to a controversial local
role in the CNS, pDCs have also been implicated in the modulation
of autoimmune Th1 and Th17 priming in secondary lymphoid or-
gans (SLOs) during early phases of EAE development. It was sug-
gested that pDCs promote Th17 priming [13], whereas we have
demonstrated that the selective abrogation of MHCII expression by
pDCs leads to increased MOG-speciﬁc Th1 and Th17 and impaired
Treg proliferation. As a result, lack of MHCII on pDCs correlates with
exacerbated EAE [14].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ulation of pDC functions as an approach to treat MS is currently an
axis of intense investigation [15]. We have previously demon-
strated that the adoptive transfer of MHCII-sufﬁcient pDCs prior to
EAE induction signiﬁcantly dampened disease severity, whereas
MCHII-deﬁcient pDC had no effect [14]. Here we investigated
whether and how pDCs may modulate the course of EAE after
disease onset. We found that when transferred during acute EAE
phase, pDCs led to dramatic disease remission. Protectionwas pDC-
dependent, correlated with reduced CNS inﬂammation, and
decreased encephalitogenic Th1 and Th17 cells. Our results
demonstrated that pDC transfer induced the recruitment of resting
endogenous pDCs to the CNS via a chemerin dependent mecha-
nism, and confer a tolerogenic environment, which, together with
local myelin peptide delivery, inhibits encephalitogenic T cells and
results in disease improvement. Therefore, modulation of CNS
inﬂammation by pDCs in EAE mice is an interesting axis of inves-
tigation to ameliorate disease clinical outcome. Up to date, almost
all current therapies in autoimmune diseases are based on the
systemic suppression of immune functions and are not curative.
Our work reinforces and validates the relevance of emerging
therapeutic concepts regarding the use of cell therapies for auto-
immune diseases.
2. Materials and methods
2.1. Mice
H2-Aae/e (MHCIIe/e) [16], Ubiquitin-GFP [17], IFN-be/e [10],
IFNARe/e [18], BDCA2-DTR [19], CD45.1 (Charles River, France) and
2D2 [20] mice were in a C57BL/6 background. WT C57BL/6 mice
were purchased from Harlan laboratories. Mice were bred and
maintained under SPF conditions at Geneva medical school animal
facility and under EOPS conditions at Charles River, France. Bone
marrow (BM) chimeric mice were generated as described [14]. All
procedures were approved by and performed in accordance with
the guidelines of the animal research committee of Geneva.
2.2. EAE induction
Active EAE was induced as described by immunizing mice with
100 mg of MOG35-55 peptide (Biotrend) emulsiﬁed in incomplete
Freund's adjuvant (BD Diagnosis) supplemented with 500 mg/ml
Mycobacterium tuberculosis H37Ra (BD Diagnosis). At the time of
immunization and 48 h later, mice also received 300 ng of pertussis
toxin (SigmaeAldrich) into the tail vein. For passive EAE induction,
encephalitogenic CD4þ T cells were generated in vitro from LN and
spleen cells of 2D2 mice as described [21]. 1e2  106 total cells
were injected i.p. into recipient mice. Mice received 67 ng of
pertussis toxin at the day of cell injection and 48 h later. Mice were
monitored daily for disease clinical symptoms, and blindly scored
as follows. 1, ﬂaccid tail; 2, impaired righting reﬂex and hind limb
weakness; 3, complete hind limb paralysis; 4, complete hind limb
paralysis with partial fore limb paralysis; 5,moribund. In some
experiments, EAE mice were treated at indicated time points with
a-NETA (Abcam) (10 mg/kg/daily), DT (100 ng/mouse), or 10 mg/mL
of MOG35-55 peptide in PBS.
2.3. BM-pDC and cDC generation
cDCs and pDCs were generated as described [22] from BM ofWT
for cDCs and WT, MHCIIe/e, Ubi-GFP, CD45.1, and IFN-be/emice for
pDCs. For some experiments, pDCs were treated with 1 mg/mL CpG-
B (Invivogen) for the last 24 h of culture.2.4. pDC and cDC adoptive transfer
pDCs and cDCs were generated and puriﬁed from BM cell cul-
tures. pDCs were enriched from BM cell cultures after 7 days or
puriﬁed ex-vivo from BMusing a pDC isolation kit (Mylteniy biotec)
according to manufacturer's instructions. Purity generally exceeded
95%. cDCs were puriﬁed by cell sorting from BM-cell cultures as
CD11chiPDCA-1e, using a MoFlowAstrios (Beckman Coulter). cDCs
and pDCswere loaded or notwith 10 mg/mLMOG35-55 or OVA323-339
peptide and 10 106 cells were injected i.v. into EAE recipient mice,
10e12 days after MOG35-55 þ CFA immunization.
2.5. Ex vivo DC isolation
DCs were isolated from Lymph nodes (LN), spleen, liver and
Spinal cord (SC). by digesting organ fragments with an enzymatic
mix containing collagenase D (1 mg/mL) and DNAse I (10 mg/mL)
(Roche) in HBSS [14]. For liver and SC, single cell suspensions were
further centrifuged through a discontinuous 30:70% percoll (Invi-
trogen) gradient.
2.6. Antibodies and ﬂow cytometry
Monoclonal antibodies used for ﬂow cytometry were from:
Biolegend; anti-CD11c (N418), antieI-Ab (AF6-120.1), anti-CD11b
(M1/70), anti-CD86 (P03), anti-PD-1 (10F.9G2) (PMP1-30); anti-
CD8 (53e6.7); anti-VLA-4 (HMB1-1), anti-Ly6C (HK1.4), anti-
ICOS-L (HK5.3); from eBioscience: anti-CD4 (GK1.5), anti-CD69
(H1.2F3), VEGFR2 (FLK1), anti-TER119 (TER-119); anti-CMKLR1
(BZ194), Anti-Foxp3 (FJK-16s), antieIL-17 (ebio17B7), anti-FLT3
(CD135) (A2F10), anti-SIGLEC H (ebio440c); from BD: antiePDCA-
1 (BST-2, CD317), anti-CD45 (30F11), anti-CD16/32 FcyRIII (clone
2.4G2), anti-CD45R/B220 (RA3-6B2), anti-CD19 (1D3), anti-CD3
(145-2C11), anti-c-kit (CD117) (2B8), anti-Sca-1 (D7), Ki67 (B56)
and antieIFN-g (XMG1.2). Anti-Ly49q (clone 2E6) was from MBL.
For ﬂow cytometry analysis of DCs, single cell suspensions were
incubated with FcBlock (anti-CD16/32 FcgRIII) for 10 min, at 4 C
and stained using antibodies against CD11c and PDCA-1 or Siglec-H.
cDCs were deﬁned as CD11chiPDCA-1 and pDCs as CD11cintPDCA-
1þ or CD11cintSiglec-Hþ. For hematopoietic progenitor analysis, red
cells from BM were lysed with NH4ClNaHCO3 buffer. BM cells were
stained with the following biotinylated lineage markers: anti-CD3,
anti-B220, anti-CD19, anti-CD11b, anti-TER119, anti- Ly6C followed
by streptavidin FITC conjugated staining. LSK BM progenitors were
deﬁned as LinSca-1þc-kitþFLT3. Microglial cells were deﬁned as
CD11cCD11bþ CD45int. Data were acquired in a Cyan™ ADP
(Beckman Coulter) and analysed using FlowJo software (Tree Star).
Intracellular cytokine stainings were done with the Cytoﬁx/
Cytoperm kit (BD) for IFN-g and IL-17 staining. Foxp3 staining was
performed with the eBioscience kit, according to manufacturer's
instructions. Cell proliferation was assessed by ﬂow cytometry us-
ing antiehuman Ki67 and respective isotype control. For IFN-g and
IL-17 staining, SC, LN and spleen cells were cultured in RPMI con-
taining 10% heat-inactivated fetal bovine serum, 50 mM 2-
mercaptoethanol, 100 mM sodium pyruvate, and 100 mM peni-
cillin/streptomycin at 37 C, 5% CO2. Cells were stimulated for 18 h
with PMA/ionomycin and Golgi stop solution (BD) was added to the
last 4 h of culture.
2.7. Immunoﬂuorescence microscopy
Mice were transcardiacally perfused with PBS followed by 4%
paraformaldehyde (PFA). Cryopreserved SC, post-ﬁxed with 4% PFA
and embedded in OCT (Sakura Finetek), were cut into 10 mm-thick
sections, and stained using primary antibodies against CD45 and
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Cy5-conjugated secondary antibodies (all from Jackson ImmunoR-
esearch Laboratories, Inc.) with DAPI (SigmaeAldrich) counter-
staining. Sections were mounted with Mowiol ﬂuorescent
mounting medium (EMD). Images were acquired with a confocal
microscope (LSM 700; Carl Zeiss, Inc.)
2.8. Histological analysis
Mice were transcardiacally perfused with PBS followed by 4%
PFA and post-ﬁxed overnight. Brain and SC, dehydrated and
embedded in parafﬁn, were cut into 2 mm thick sections and stained
with Mayer's hemalum, differentiated in acidic-alcohol and co-
stained with eosin and coverslipped with DePeX mounting me-
dium (Serva Electrophoretics GmbH, Heidelberg, Germany) using
Tissue Tek Prisma slide stainer (Sakura Seiki C.o., Nagano, Japan).
2.9. Statistical analysis
Statistical signiﬁcance was assessed by the two-tailed unpaired
Student's t test or 1-way ANOVAwith Bonferroni post Hoc test. EAE
incidence was analysed using the 2-way ANOVA with Bonferroni
post Hoc test, using Prism 5.0 software (GraphPad Software).
3. Results
3.1. Adoptive transfer of pDCs during EAE acute phase inhibits CNS
inﬂammation and induces disease remission
In order to explore a potential therapeutic role for pDCs in EAE,
we adoptively transferred in vitro bone marrow (BM) derived WT
MOG35-55 loaded pDCs into C57BL/6 mice after disease onset, 12
days after immunization with MOG35-55 þ CFA. Strikingly, whereas
clinical scores of control non pDC-injected mice continued to rise,
those of pDC-injected mice stayed stable for few days post-pDC
transfer, and then rapidly decreased, resulting in a signiﬁcant in-
hibition of EAE (Fig. 1A). Clinical symptoms almost completely
disappeared 10 days after pDC injection (Fig. 1A). Moreover, mice
presenting a clinical score of 3 at the time of pDC transfer either
signiﬁcantly recovered or exhibited stabilized disease develop-
ment, whereas scores of control animals maintained their pro-
gression (Supplementary Fig. 1A, B). Consistent with an
amelioration of clinical scores, as early as four days post-pDC
transfer, inﬂammatory foci were reduced in spinal cord (SC) of
pDC-transferred mice, compared to control EAE mice (Fig. 1B). In
agreement with reduced CNS inﬂammation, microglial cells
downmodulated the expression of MHCII molecules (Fig. 1C). In
spite of this, four days after pDC transfer, we did not observe any
differences regarding the frequency of CD4þ and CD8þ T cells
inﬁltrating the SC (Supplementary Fig. 2A), nor in the expression of
VLA-4 by T cells (Supplementary Fig. 2B) between pDC transferred
and control EAE mice. Consequently, T cell migration from SLOs to
SC was not altered upon pDC transfer. However, the expression of
PD-1, a molecule that delivers negative signals to T cells [23], was
increased on SC-inﬁltrating CD4þ T cells one day after pDC transfer
(Fig. 1D). Remarkably, encephalitogenic Th1 (at day 4 and 9 after
pDC transfer) and Th17 frequencies (at day 9 after pDC transfer)
were substantially decreased in SC of pDC-transferred mice
(Fig. 1E). These data demonstrate that adoptive transfer of BM-
derived pDCs after EAE onset induces a strong and rapid
improvement of disease clinical symptoms and CNS inﬂammation.
This effect appeared to be pDC-speciﬁc, since transfer of MOG35-55-
loaded cDCs did not signiﬁcantly impact EAE development
(Supplementary Fig. 3A). In addition, although most of our exper-
iments were done using 5e10 106 of transferred pDCs, a similarlyefﬁcient therapeutical effect was observed by using only 1  106
cells (Supplementary Fig. 3B). Importantly, adoptively transferred
MOG35-55 loaded ex vivo BM resident pDCs efﬁciently induced EAE
amelioration (Fig. 1F), demonstrating that in vivo, terminally
differentiated pDCs efﬁciently inhibit the disease.
3.2. pDC transfer induces the selective recruitment of endogenous
pDCs to the CNS and inhibits EAE effector phase
To determine the mechanisms accounting for pDC-mediated
EAE amelioration, we analysed the body distribution of injected
BM-pDCs derived from Ubiquitin-GFP mice. Two days post-
injection, GFPþ pDCs were detectable in LN, spleen and inﬂamed
SC (Fig. 2A). In addition, a very low frequency of GFPþ pDCs was
observed in the liver and the BM (data not shown). In situ immu-
noﬂuorescence staining of SC revealed that, GFPþ pDCs localized
within EAE lesions (Fig. 2B, top), expressed the pDC-speciﬁc marker
PDCA-1 (yellow arrows) and were surrounded by endogenous
inﬁltrating pDCs (white arrows) (Fig. 2B, bottom). While the fre-
quencies of cDCs, macrophages and microglial cells were similar in
SC of pDC-transferred and control EAEmice (Supplementary Fig. 4),
we observed a massive (six-fold) increase of total pDC frequencies
in SC of pDC-transferred EAE mice (Fig. 2C). Injected pDCs (GFPþ)
represented only 25% of total SC pDCs (Fig. 2D), suggesting that
endogenous pDCs were recruited to the SC following exogenous
pDC transfer. In agreement, increased endogenous pDC frequencies
in SC of pDC-transferred animals did not result from local pDC
proliferation (data not shown). Therefore, we hypothesized that
they would be recruited from the BM, where pDCs originate from.
Accordingly, four days post-pDC transfer into EAE mice, we
observed in the BM a substantial increase of total pDC frequencies,
with only a minor proportion consisting of transferred GFPþ pDCs
(Supplementary Fig. 5A, B). These results suggest that the increase
in endogenous pDC frequency could be due to active proliferation
or enhanced de novo generation. Ki67 staining revealed a negligible
proliferation rate of pDCs in the BM, in both control and pDC-
transferred EAE mice (Supplementary Fig. 5C). In contrast, we
observed a signiﬁcant increase in LSK (lineage-negative, SCA1þ, c-
Kitþ) progenitor's frequencies in the BM, one-day post-pDC transfer
(Supplementary Fig. 5D), suggesting a general enhancement of
hematopoietic cell generation. In line with this notion, both cDC
and pDC frequencies were signiﬁcantly increased in LN, 4 days after
pDC-transfer (Supplementary Fig. 5E). Furthermore, at the same
time point, BM-resident pDCs, from pDC-transferred mice, exhibi-
ted an upregulation of Ly49q, a marker of fully differentiated pDCs
[24] compared to control mice (Supplementary Fig. 5F). Altogether,
these data show that pDC transfer in EAE mice increases hemato-
poietic cell generation in the BM, leading to enhanced cDC and pDC
frequencies in SLOs, and resulting in the selective recruitment of
pDCs to the CNS.
Increased pDC frequencies in SC of EAE mice following pDC
transfer suggests that these cells might play a protective role locally
in the CNS. To test this hypothesis, we induced passive EAE by
injecting in vitro differentiated MOG35-55-speciﬁc 2D2 CD4þ T cell
effectors [14]. Upon both mild (1  106 2D2 effectors, Fig. 2E, left)
and strong (2  106 2D2 effectors, Fig. 2E, right) EAE induction,
pDCs injected at early disease clinical symptoms onset were able to
inhibit disease development, with signiﬁcantly reduced EAE inci-
dence and clinical scores. These results demonstrated that pDC
transfer inhibits CNS-local effector phase of EAE.
3.3. Recruitment of endogenous pDCs to the inﬂamed CNS mediates
EAE protection
Our data strongly suggests that endogenous pDCs recruited to
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Indeed, exogenous MOG35-55 loaded cDCs, which did not signiﬁ-
cantly ameliorate EAE upon transfer (Supplementary Fig. 3A;
Fig. 3A), also did not induce endogenous pDC recruitment to SC
(Fig. 3B). To ﬁrmly demonstrate that endogenous pDC recruitment
to SC was necessary for disease amelioration following exogenous
pDC transfer, we used a genetic mouse model to deplete endoge-
nous pDCs. For this purpose, CD45.1WT pDCs were transferred into
BDCA-2 DTR EAE mice [19], and mice were injected or not with DT
at the same time pDCs were transferred. Endogenous pDCs were
efﬁciently depleted in the spleens of DT-treated mice (not shown)
[25]. However, exogenous (CD45.1þ) pDC numbers reaching the SCwere not affected (Fig. 3C, left), but as a consequence of BDCA-2
DTR pDC depletion, endogenous pDC recruitment to the SC was
substantially impaired in DT treated, compared to untreated ani-
mals (Fig. 3C, right). Importantly, EAE amelioration following
MOG35-55 loaded pDC transfer was totally abrogated in DT treated
mice (Fig. 3D). Therefore, endogenous pDC recruitment to SC after
pDC transfer is mandatory to confer EAE protection.
3.4. Chemerin-CMKLR1 axis mediates endogenous pDC recruitment
to the CNS following pDC transfer
Although a speciﬁc receptor mediating pDC migration to
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and chemotactic factors, as well as its receptors have been related
to pDC homing to peripheral tissues under pathological conditions
[26]. In order to identify possible mechanism(s) responsible for pDC
recruitment to CNS, we analysed the implication of Chemerin/
CMKLR1 (chemerin receptor), an axis linked to pDC migration in
humans [27]. First, and as previously observed [28], we found that
SC of EAE mice contained increased chemerin mRNA levels,
compared to naive SC (Fig. 4A). In addition, in spleens of EAE mice,pDCs expressed high levels of CMKLR1, compared to cDCs, irre-
spective of pDC transfer (Fig. 4B). Interestingly, the frequency of
pDCs expressing CMKLR1 was substantially increased in SC as early
as one day after pDC transfer, and was sustained four days after
transfer (Fig. 4C). In contrast, CMKLR1 expression remained low
and unaltered on SC inﬁltrating cDCs from both pDC-transferred
and control EAE mice (Fig. 4C). In order to test a possible involve-
ment of the Chemerin/CMKLR1 axis in the recruitment of endog-
enous pDCs to the SC following pDC transfer, we treated pDC
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antagonist, a-naphthoyl ethyltrimethylammonium iodide (a-
NETA), known to block CMKLR1þ cell migration [29]. a-NETA
treatment, for 3 consecutive days following pDC transfer, signiﬁ-
cantly blocked pDC recruitment to SC of EAE mice (Fig. 4D). These
results demonstrate that pDC recruitment to SC following pDC
transfer is mediated by the chemerin-CMKLR1 axis. However, given
that this molecule not only interferes with pDC homing but also
affects migration of additional key effector cells in EAE, such as
macrophages and microglial cells (Supplementary Fig. 6) [29], we
could not use this experimental approach to evaluate the impact of
blocking endogenous pDC recruitment to the CNS on diseaseevolution.3.5. Transferred pDCs provide myelin antigen and modulate pDC
activation state in the CNS
pDCs are important producers of type-I IFN upon viral in-
fections. In addition, IFN-b is widely used as a treatment for MS.
However, the precise mechanisms involved in IFN-b mediated
disease amelioration are still incompletely understood. In order to
check whether IFN-b was involved in pDC-mediated protection in
EAE, we transferred IFN-bko or WT MOG35-55 loaded pDCs into EAE
recipient mice. Both WT and IFN-bko pDCs mediated the same level
of disease inhibition, thus excluding a role for IFN-b production by
exogenous pDCs in disease amelioration (Fig. 5A). Similarly, WT
pDCs induced the same level of disease amelioration (Fig. 5B, left),
as well as a similar increase in SC pDC frequencies (Fig. 5B, right),
when transferred into either WT or IFN-I receptor deﬁcient
(IFNARe/e) EAE recipient mice. Altogether, these results ﬁrmly rule
out a role for IFN-I in disease amelioration induced by pDC transfer.
We have previously showed that when transferred prior to EAE
induction, pDC-mediated protection was MHCII dependent [14].
However, in post-EAE settings, disease inhibition was as efﬁcient
using either MHCII sufﬁcient or deﬁcient pDCs (Fig. 5C), suggesting
a MHCII independent role for injected MOG35-55 loaded pDCs in
regulating CNS-inﬂammation. A requirement for MHCII expression
by endogenous pDCs, that are recruited to the SC after pDC injec-
tion, was also ruled out, since EAE protection after WT pDC transfer
was not altered in mice selectively lacking MHCII expression by
pDCs (mMTxpIIIþ IVe/e:WT BM chimeric mice, as described before)
[14] (Supplementary Fig. 7A). Surprisingly, EAE protection was
abolished when transferred pDCs were either unloaded or loaded
with an irrelevant peptide (OVA323-339), prior to their injection
(Fig. 5D). Importantly, in contrast to high peptide concentrations
(100e200 mg/mL) that have been described to confer EAE amelio-
ration [30], intravenously injection of 10 mg/mL of MOG35-55 pep-
tide, the concentration used to load pDCs, did not confer any
disease improvement (Supplementary Fig. 7B), emphasizing the
requirement of pDCs for therapeutic effect. Notably, disease
amelioration in EAE mice injected with MOG35-55-loaded WT or
MHCIIe/e pDCs correlated with pDC recruitment to SC (Fig. 5E). In
contrast, pDC frequencies were not increased in SC of EAE mice
injected with unloaded pDCs, in which no disease protection was
observed (Fig. 5D, E), again supporting the need of endogenous pDC
recruitment to SC for pDC therapeutic effect.
In order to investigate the features related to pDC tolerogenic
effect, we analysed pDC phenotype in SC of EAE mice. Irrespective
of pDC transfer, CNS pDCs expressed lower levels of CD86,
compared to cDCs (Fig. 6A). Conversely, the expression of CD69 by
endogenous pDCs was substantially downregulated upon pDC
transfer (Fig. 6B). These ﬁndings suggest that the inﬂammatory
status of pDCs in SC from EAE mice was markedly altered following
pDC transfer. To determine whether the lack of pDC activation is
involved in the pDC transfer-therapeutic effect, we treated pDCs
with CpG-B prior to their injection. CpG-treated pDCs did not
induce in situ upregulation of CMKLR1 by pDCs (Fig. 6C), neither the
recruitment of endogenous pDCs to SC of EAE mice (Fig. 6D).
Importantly, we further observed that injection of CpG-B activated
MOG35-55 loaded pDCs did not confer any signiﬁcant disease
amelioration, compared to untreated MOG35-55 loaded pDCs
(Fig. 6E), supporting a role for steady-state pDCs in disease
amelioration. Altogether, these results demonstrate that steady-
state pDC-transfer promotes a pDC-dependent tolerogenic envi-
ronment in SC of EAE mice, resulting in the general suppression of
EAE pathogenicity and clinical symptoms.
Fig. 5. Transferred pDCs deliver myelin antigen to SC. (AeC) EAE was induced in indicated mice and BM-derived, WT or IFN-be/e (A), WT (B) WT or MHCIIe/e (C) MOG35-55-loaded
pDCs were transferred into mice during EAE acute phase (red arrows). Clinical scores were followed daily. (A) EAE clinical scores in WT mice transferred with WT or IFN-be/e pDCs.
(B) EAE clinical scores from WT or IFNARe/emice transferred or not with WT pDCs (left). Total pDC frequencies were analysed in SC of mice four days after pDC transfer (right). (C)
EAE clinical scores from WT mice transferred or not with WT or MHCIIe/e pDCs. Data are representative of 5 independent experiments with 8 mice/group each. (D, E) EAE was
induced in WT mice and BM-derived WT or MHCIIe/e pDCs, loaded or not with MOG35-55 or OVA323-339 as indicated, were transferred into mice during EAE acute phase. (D) Clinical
scores were followed daily. (E) Total pDC frequencies were analysed four days after pDC transfer in SC of mice from. (AeE) Data are representative of 3 independent experiments
with 8 mice/group each. Data represent mean ± SEM. (A, B left panel, C, D) 2-way ANOVA with Bonferroni post hoc test; (B right panel) Standart two-tailed Student's t test; (E) 1-
way ANOVA with Bonferroni post hoc test * P < 0.05; **P < 0.01; ***P < 0.001.
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In EAE and MS, whether pDCs have a prominent pathogenic or
tolerogenic role is still controversial. Activated pDCs, through the
production of pro-inﬂammatory cytokines, such as TNF and IL-6,
have been claimed to be pathogenic and promote disease pro-
gression, both in mice and humans. In agreement, pDCs were
shown to be pathogenic in EAE by inducing Th17 responses [13]. On
the other hand, constitutive or antibody mediated pDC depletion
during peak disease correlates with EAE exacerbation [12,31]. We
have previously demonstrated that pDCs can present myelin-
derived autoantigens via MHCII to CD4þ T cells in an EAE context
and promote the expansion of suppressive Treg cells [14]. In the
present work, in order to explore pDC tolerogenic potential in a
therapeutic EAE setting, we performed adoptive transfer of syn-
genic pDCs after disease onset. Strikingly, pDCs induced a rapid and
substantial amelioration of both CNS inﬂammation and EAE clinical
scores upon transfer into sick mice. Transferred pDCs rapidly
reached the SC, localized in lesion areas in the CNS, and inhibited
already primed encephalitogenic MOG35-55-speciﬁc 2D2 CD4þ T
effector cells, pointing out to a local immunoregulatory role of
these cells during EAE effector phase. However, we cannot rule out
a possible systemic impact on immune cells in other organs
following pDC transfer, and future studies will determine whether
this might be beneﬁcial in other inﬂammatory diseases.
The idea that few exogenous pDCs reaching the SC could confer
such strong disease amelioration seemed rather puzzling. When
investigating the cellular compartments in the SC after pDC
transfer, we observed a tremendous increase in total pDC fre-
quency, but not of other cell types such as cDCs, macrophages ormicroglial cells, suggesting a speciﬁc recruitment of endogenous
pDCs to the SC. Importantly, selective depletion of endogenous
pDCs completely abrogated disease amelioration following pDC
adoptive transfer. Thus, the accumulation of endogenous pDCs in
the CNS of EAE mice following pDC transfer accounts for EAE pro-
tection. Interestingly, we observed a signiﬁcant increase in de novo
HSC progenitors' generation in the BM of pDC transferred
compared to control EAE mice. One possibility is that upon transfer,
few exogenous pDCs reach the BM and locally produce a factor
promoting HSC generation. In agreement, it has been recently
demonstrated that angiopoietin-like 7, which is produced by pDCs,
regulates the expansion and repopulation of human hematopoietic
stem and progenitor cells [32]. Alternatively, LSK progenitor in-
crease in BM might reﬂect a physiologic demand for pDC genera-
tion, as an indirect consequence of pDC-recruitment to the CNS
following pDC transfer. Newly generated BM-pDCs would then be
speciﬁcally recruited to the inﬂamed CNS through chemerin/
CMKLR1 axis, an inﬂammatory chemotactic factor that is involved
in pDC migration [33]. In vivo, chemerin expression correlated with
pDC inﬁltration into peripheral tissues during autoimmune dis-
eases, such as SLE [26]. Most importantly, chemerinwas detected in
intralesional cerebrovascular endothelial cells of MS patients, and
its receptor is expressed by pDCs [34]. In agreement, we observed
an increase in chemerin expression in the SC of EAEmice compared
to naïve mice. Furthermore, we found a signiﬁcant and speciﬁc
increase in the expression of CMKLR1 (or Chem23R) by pDCs in the
SC of pDC-transferred mice. Blockade of CMKLR1 induced cell
migration abrogated pDC recruitment to the SC, demonstrating that
following pDC transfer, endogenous pDC homing to inﬂamed CNS is
mediated by the chemerin/CMKLR1 axis. However, microglia cells
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and EAE clinical and histological disease was found less severe in
CMKLR1 deﬁcient mice when compared to WT counterparts [28].
One possibility is that under inﬂammatory EAE condition, activated
CNS pDCs indeed promote disease pathogenesis, and that in
CMKLR-1 deﬁcient mice, pDC recruitment to the CNS is impairedand mice consequently develop attenuated EAE. In our settings of
pDC transfer in EAE mice, endogenous pDCs would be deﬂected
from pro-pathogenic to pro-tolerogenic functions after down-
modulation of their activation state.
In our system, pDC protective role was not related to type I IFN
production. Rather, a “non-activated” state for pDCs seemed to be
F.V. Duraes et al. / Journal of Autoimmunity 67 (2016) 8e18 17required. Accordingly, CpG-B activated pDCs did not induce
endogenous pDC recruitment to the CNS of EAE mice, neither did
they conferred any signiﬁcant level of disease amelioration, when
compared to steady-state pDCs. Strikingly, resting pDCs transferred
in EAE mice downmodulated the activation of local pDCs. Notably,
expression of CD69, a marker for activated pDCs [35], was sub-
stantially reduced on endogenous pDCs recruited to SC after pDC
transfer. Therefore, the combination of several pDC-speciﬁc fea-
tures in the CNS: i) increased pDC frequencies; ii) modulation of
pDC activation status; iii) ability to provide myelin antigen; iv)
production of a state permissive for tolerance, altogether likely
contribute to pDC protective role in EAE. MHCII deﬁcient pDCs,
were able to induce the same degree of disease inhibition
compared toWT pDCs, ruling out a role forMHCII mediated antigen
presentation by exogenous pDCs in this protective setting. Our data
support a local inhibition of encephalitogenic effector T cells in the
CNS of EAE mice after pDC transfer. First, as early as 1 day post-pDC
injection, T cells up-regulated the inhibitory molecule PD-1, and
second, after 4 days, we observed reduced frequencies of enceph-
alitogenic Th1 and Th17 cells in the SC.
Current available antibody based therapies target various im-
mune cell populations mediating the autoimmune chronic reaction
for the treatment of MS, rheumatoid arthritis and other autoim-
mune diseases. Autologous stem cell transplantations are currently
tested as immunotherapy for autoimmune diseases, including MS
[36]. Although visionary, therapies using terminally differentiated
cells for the treatment of autoimmune diseases are emerging and
are up to date mainly focused on the adoptive transfer of Tregs.
Both preclinical and clinical data in support for Treg infusional
therapy suggest that ex vivo expanded, autologous Tregs might
have a beneﬁcial effect in patients for T1D [37] and SLE [38,39]. In
MS, the rationale for Treg therapy is less clear. Indeed, while Tregs
infused prior EAE induction confer protection, their therapeutic
value is considerably diminished when infused after disease initi-
ation [40,41]. Accordingly, Tregs immersed in inﬂamed CNS of EAE
mice lost their suppressive activity [42]. Whether Tregs acquire
suppressive functions and are directly linked to EAE protection
after pDC-transfer will require further investigation.
Adoptive transfer of tolerogenic APCs for MS therapies has also
been considered. If these approaches efﬁciently suppress EAEwhen
injections were performed prior disease induction [43], tolerogenic
APCs however impact mainly the priming of encephalitogenic T
cells, and no efﬁcacy was consequently proven when effector T cell
responses and disease symptoms are already established. These
observations make our results even more attractive in the sense
that pDC suppressive effect on established EAE is not APC depen-
dent, and directly impact disease effector phase in the CNS.
Together, our results highlight pDCs as important mediators in MS
immunotherapy. Manipulation of pDC numbers as well as
enhancement of pDC potential immunoregulatory properties could
be exploited in order to treat MS patients.Competing interests
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